Clinical Report · Case #25-0328-6178
Maria K., 52 — Breast cancer follow-up
Female · Age 52 · Case ID: 25-0328-6178 · March 15, 2025 · ER+ / PR+ / HER2- (IHC 1+)
Report generated: May 4, 2025 · By: Dr. L. Hernandez (Med Onc), Dr. T. Lee (Rad Onc), Dr. R. Singh (Path Onc), Dr. S. Patel (Radiology)
Protected by a multidisciplinary review platform. All reports are confidential.
Final interpretation is provided by experienced specialists.
Overall Status · Next 12 Weeks
Partial response — treatment on track
Target lesion decrease -18 mm (-57%). PET/CT and CA 15-3 trending downward.
Beyond a Better Decision
From anxiety to clarity
What patients tell us changes when their report is read by OncoXAI.
Before
Confusion & worry
"I have so much information, but I don't know what it means."
"Every new result makes me more anxious."
"I don't know if I'm doing the right thing."
"I feel I'm moving forward, but not sure in the right direction."
After
Calm & in control
"I finally understand exactly what is happening in my body."
"There's a clear plan, and I feel I'm on the right track."
"I have a way to follow along and see what's next."
"I've shifted from 'why is this happening to me?' to 'what's my next step?'"
Tumor Response
(RECIST 1.1)
−57%
Target lesion decreased from 32 mm to 14 mm (−57%). Latest follow-up shows continued reduction.
Cardiac & Organ Function
LVEF 62%
Echocardiogram shows normal range. AST 24 U/L, ALT 23 U/L, Creatinine 0.82 mg/dL. All in normal.
Tumor Marker
CA 15-3 — 18 U/mL
Decreased from 26 U/mL to 18 U/mL (−31%). CA 27.29: 19 U/mL. Trend consistent with response.
In Plain Words
What this means for you
Your results show a meaningful response — a reduction in measurable cancer on imaging, improving tumor markers, and stable organ and heart function. This is a positive sign that your current treatment is working. We recommend continuing the plan as it is, with regular monitoring to make sure this progress continues. Although some symptoms (fatigue, mild bone pain) can still be present, which are common and seem to be improving.
This plan is consistent with global NCCN, ESMO and ASCO guidelines for hormone-positive breast cancer with partial response. We will keep monitoring your progress with imaging and labs at planned intervals and adjust your plan if we see anything change. Please contact us if new or worsening symptoms appear between visits. We are here to support you.
CA 15-3 Trend (U/mL)
Cycles 1 – 4
Steady decline from 26 to 18 U/mL over 4 cycles, aligned with response to treatment.
Hematology (CBC)
StableWBC 6.1 K/μL, Hb 12.3 g/dL, ANC 3.2 K/μL, Platelets 184 K/μL. No concerns noted and within safe range for treatment.
Biomarkers & pathology
StableKi-67 15% (prior 30%). ER+: 90%, PR+: 80%, HER2- (IHC 1+). PIK3CA mutation not detected. Comprehensive molecular profile in report.
Toxicities (CTCAE v5)
ManageableFatigue grade 1, mild bone pain grade 1, alopecia grade 1. No severe toxicities reported. Continue supportive care.
Watchlist for next visit
3 itemsRepeat PET/CT for continued response. Monitor liver function and CA 15-3 trend. Evaluate bone density at 6-12 months (consider DEXA).
Next Steps · Our Stage-Guided Approach
Your recommended plan forward
- 1
Continue current treatment plan
Stay on current therapy. No changes needed at this time. Continue supportive care for symptoms.
- 2
Monitor response & safety
Follow-up imaging in 12 weeks. Labs and tumor markers each cycle. Report any new symptoms.
- 3
Review & adjust as needed
We'll review your next results together and adjust the plan if needed to keep you on the best path forward.
This report is compiled based on a review of the provided data by the OncoXAI expert team. It is not a substitute for professional medical advice. Always consult your treating physician for medical decisions.
ONE UPLOAD. ONE MULTIDISCIPLINARY REVIEW.
Before making your next treatment decision, understand the complete clinical picture.
1. Upload
Send your medical reports and images securely.
2. We review
Our multidisciplinary experts analyze and integrate all your information.
3. You receive
Get one clear, personalized report with expert recommendations.
It's safe, simple and confidential.